Access to treatment in a Patient Support Program for patients with severe eosinophilic asthma in Colombia
Acceso al tratamiento en un Programa de Soporte al Paciente con Asma grave eosinofílica en Colombia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Introduction. Benralizumab is an effective monoclonal antibody in the treatment of patients with uncontrolled severe eosinophilic asthma despite adequate adherence and inhaler technique and the administration of high-dose inhaled corticosteroids and long-acting β-agonists. Innovative therapies frequently encounter obstacles within healthcare systems, particularly in terms of providing patients with timely and effective access. Patient Support Programs (PSP) can help to reduce these access barriers by improving timelines and identifying milestones that different actors in the system can focus on to achieve more effective access. Objective. To compare the outcomes of a patient support program for patients with severe eosinophilic asthma and access to therapy during 2021 and 2022 in Colombia.
Materials and Methods Retrospective observational descriptive analysis of a support program for patients with severe eosinophilic asthma during 2021-2022 in Colombia.
Results. Female gender predominated in both periods (69.8% and 76.2% respectively). the mean age was 52 years (SD±11,4) (p value 0,395) in 2021 and 52 years (SD±11,7) in 2022. The average time between prescription and drug delivery remained at 32 days without increase between the years. When comparing the two periods, there was a decrease of 3 days in the average time for treatment authorization since linking the program, of 2 days in the average time for drug delivery since authorization and of 5 days in the average time for drug delivery since linking the program. The main medication access barriers were scheduled application appointment (76%) and appointment scheduling <5 days (6%) over the two years.
Conclusions. Patient support programs in severe eosinophilic asthma impact patient pathway times, inequity between assurance and social inequity, reducing variability in access between population groups. Follow-up of the program evidences a greater experience in the processes of access to the treatment of severe eosinophilic asthma.
Article visits 441 | PDF visits 362
Downloads
- Global Asthma Report. The Global Asthma Report 2022. Int J Tuberc Lung Dis [Internet]. 2022;26(1-102).
- Nannini LJ, Luhning S, Rojas RA, Antunez JM, Miguel Reyes JL, Cano Salas C, et al. Position statement: asthma in Latin America. IS short-acting beta-2 agonist helping or compromising asthma management? Journal of Asthma. 2021;58(8):991-4. doi: 10.1080/02770903.2020.1777563
- Sociedad Española de Neumología y Cirugía Torácica. GEMA 5.2. Guía Española para el Manejo del Asma. [Internet] s.f.
- FitzGerald JM, Tran TN, Alacqua M, Altraja A, Backer V, Bjermer L, et al. International severe asthma registry (ISAR): protocol for a global registry. BMC Medical Research Methodology. 2020;20(1):212. doi: 10.1186/s12874-020-01065-0
- Wang E, Wechsler ME, Tran TN, Heaney LG, Jones RC, Menzies-Gow AN, et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. Chest. 2020;157(4):790-804. doi: 10.1016/j.chest.2019.10.053
- Maspero J, Pavie J, Torres-Duque CA, Montero-Arias F, Cerino-Javier R, Rovira F, et al. Toward a better understanding of severe asthma phenotypes in Latin America: results from the PREPARE study. Curr Med Res Opin. 2023;39(4):627-38. doi: 10.1080/03007995.2023.2174328
- Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033-9. doi: 10.1056/NEJM199010113231505
- INVIMA. [Internet]. Consulta de datos de producto: Fasenra- BenralizumabRecuperado: https://consultaregistro.invima.gov.co/Consultas/consultas/consreg_encabcum.jsp
- Hurtado ES, Gallego YR, Rodriguez MA. Efficacy of Benralizumab in patients with severe eosinophilic asthma. Pneumologie. 2023;77(S 01):Po 134. doi: 10.1055/s-0043-1760925
- Álvarez-Gutiérrez FJ, Blanco-Aparicio M, Plaza V, Cisneros C, García-Rivero JL, Padilla A, et al. Documento de consenso de asma grave en adultos. Actualización 2020. Open Respir Arch. 2020;2(3):158-74. doi: 10.1016/j.opresp.2020.03.005
- Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. The Lancet Respiratory Medicine. 2022;10(1):47-58. doi: 10.1016/S2213-2600(21)00352-0
- González D, Martinez I, Ortega L. Eficacia de las terapias biológicas disponibles en Colombia para el asma eosinofílica severa: un metanálisis en red. Bogotá: Universidad del Rosario-Universidad CES; 2022. Recuperado: https://repository.urosario.edu.co/server/api/core/bitstreams/4f24aa92-c9fc-47c9-8bd9-fd7d7c57d363/content
- Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, et al. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J Allergy Clin Immunol Pract. 2021;9(12):4381-4392.e4. doi: 10.1016/j.jaip.2021.07.058
- D’Amato M, Menzella F, Altieri E, Bargagli E, Bracciale P, Brussino L, et al. Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. Front Allergy. 2022;3:881218. doi: 10.3389/falgy.2022.881218
- Guerrero R, Gallego AI, Becerril-Montekio V, Vásquez J. Sistema de salud de Colombia. Salud Pública de México [Internet]. Instituto Nacional de Salud Pública; 2011 [citado 14 de mayo de 2023];53:s144-55. Recuperado: http://www.scielo.org.mx/scielo.php?script=sci_abstract&pid=S0036-36342011000800010&lng=es&nrm=iso&tlng=es
- Ministerio de Salud y Protección Social. Boletín Gasto de bolsillo en medicamentos. [Internet]. 2022.
- Sacristán JA, Artime E, Díaz-Cerezo S, Comellas M, Pérez-Carbonell L, Lizán L. The Impact of Patient Support Programs in Europe: A Systematic Literature Review. Patient. 2022;15(6):641-54. doi: 10.1007/s40271-022-00582-y
- Levy ML, Bacharier LB, Bateman E, Boulet L-P, Brightling C, Buhl R, et al. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. npj Prim Care Respir Med. Nature Publishing Group; 2023;33(1):1-13. doi: 10.1038/s41533-023-00330-1
- Solé D, Aranda CS, Wandalsen GF. Asthma: epidemiology of disease control in Latin America-short review. Asthma Res Pract. 2017;3:4. doi: 10.1186/s40733-017-0032-3
- Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J, et al. Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract. 2014;27(1):46-52. doi: 10.1177/0897190013504954
- Hovdenak Jakobsen I, Vind Thaysen H, Laurberg S, Johansen C, Juul T. Patient-led follow-up reduces outpatient doctor visits and improves patient satisfaction. One-year analysis of secondary outcomes in the randomised trial Follow-Up after Rectal Cancer (FURCA). Acta Oncologica. 2021;60(9):1130-9. doi: 10.1080/0284186X.2021.1950924
- Bran-Piedrahita L, Valencia-Arias A, Palacios-Moya L, Gómez-Molina S, Acevedo-Correa Y, Arias-Arciniegas C, et al. Barreras de acceso del sistema de salud colombiano en zonas rurales: percepciones de usuarios del régimen subsidiado. Hacia la Promoción de la Salud. 2020;25(2):29-38. doi: 10.17151/hpsal.2020.25.2.6
- Ledezma-Morales M, Amariles P, Vargas-Peláez CM, Rossi-Buenaventura FA, Amariles P, Vargas-Peláez CM, et al. Estrategias para promover el acceso a medicamentos de interés en salud pública: revisión estructurada de la literatura. Revista Facultad Nacional de Salud Pública. 2020;38(1). doi: 10.17533/udea.rfnsp.v38n1e332273
- Martínez-Moragón E, García-Moguel I, Nuevo J, Resler G, Antépara I, Arismendi-Núñez E, et al. Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study). BMC Pulmonary Medicine. 2021;21(1):417. doi: 10.1186/s12890-021-01785-z
- Ganguli A, Clewell J, Shillington AC. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence. 2016;10:711-25. doi: 10.2147/PPA.S101175
- Argenziano G, Amerio P, Aragone MG, Baggini G, Baldari M, Castelli G, et al. Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy. Patient Prefer Adherence. 2021;15:2551-62. doi: 10.2147/PPA.S326498
- Farias FAC de, Dagostini CM, Bicca Y de A, Falavigna VF, Falavigna A. Remote Patient Monitoring: A Systematic Review. Telemed J E Health. 2020;26(5):576-83. doi: 10.1089/tmj.2019.0066
Information
Journal history
Keywords
QR code
Funding
Directories and indexes
